Prime Healthcare Services - St Michael's Medical Center
Welcome,         Profile    Billing    Logout  
 4 Trials 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Slim, Jihad
Sound, NCT04826562: Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

Active, not recruiting
4
40
US
Dolutegravir/Lamivudine, Dovato
Saint Michael's Medical Center, ViiV Healthcare
Human Immunodeficiency Virus
10/23
12/23
NCT06694805: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Recruiting
3
332
Europe, US
CAB LA + RPV LA, Oral ART
ViiV Healthcare
HIV Infections
05/26
12/27
NCT06214052: VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Completed
2
22
Europe, Canada, US, RoW
VH4524184, Matching Placebo, Antiretroviral therapy
ViiV Healthcare, GlaxoSmithKline
HIV Infections
06/24
06/24
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed
2
44
Europe, Canada, US, RoW
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
NCT05869643: A Clinical Trial of STP0404 in Adults With HIV-1 Infection

Recruiting
2
36
US
Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo
ST Pharm Co., Ltd.
HIV-1-infection
12/25
12/25
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Terminated
2
21
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare
HIV Infections
08/24
08/24
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active, not recruiting
2
128
US
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
ViiV Healthcare
HIV Infections
11/24
01/29
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Culpepper, Don
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Shulka, Prerak
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Afaq, Safia
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Slim, Jihad
Sound, NCT04826562: Switch to DOVATO in Patients Suppressed on Biktarvy (SOUND)

Active, not recruiting
4
40
US
Dolutegravir/Lamivudine, Dovato
Saint Michael's Medical Center, ViiV Healthcare
Human Immunodeficiency Virus
10/23
12/23
NCT06694805: A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

Recruiting
3
332
Europe, US
CAB LA + RPV LA, Oral ART
ViiV Healthcare
HIV Infections
05/26
12/27
NCT06214052: VH4524184 Proof-of-Concept in Treatment-Naïve Adults Living With HIV-1

Completed
2
22
Europe, Canada, US, RoW
VH4524184, Matching Placebo, Antiretroviral therapy
ViiV Healthcare, GlaxoSmithKline
HIV Infections
06/24
06/24
CINNAMON, NCT06039579: Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed
2
44
Europe, Canada, US, RoW
VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo
ViiV Healthcare
HIV Infections
06/24
06/24
NCT05869643: A Clinical Trial of STP0404 in Adults With HIV-1 Infection

Recruiting
2
36
US
Low-dose STP0404 (Pirmitegravir), Medium-dose STP0404 (Pirmitegravir), High-dose STP0404 (Pirmitegravir), Placebo
ST Pharm Co., Ltd.
HIV-1-infection
12/25
12/25
NCT06061081: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1

Terminated
2
21
Europe, US, RoW
VH3739937, Placebo
ViiV Healthcare
HIV Infections
08/24
08/24
EMBRACE, NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active, not recruiting
2
128
US
VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20
ViiV Healthcare
HIV Infections
11/24
01/29
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Culpepper, Don
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Shulka, Prerak
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26
Afaq, Safia
PROMISE-US, NCT05388474: A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Recruiting
N/A
200
US
No ibalizumab or Pre-ibalizumab treatment, Ibalizumab, On ibalizumab treatment
Theratechnologies, Excelsus Statistics Inc., Health Psychology Research Group (HPR), ICON Clinical Research
HIV Infections, Multi-Antiviral Resistance
12/25
06/26

Download Options